{"id":"W3197001173","doi":"10.1093/rheumatology/keab685","title":"Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study","year":2021,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"Gilead Sciences","keywords":"Medicine; Double blind; Placebo; Lupus erythematosus; Dermatology; Cutaneous Lupus Erythematosus; Internal medicine; Physical therapy; Immunology; Pathology; Alternative medicine; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002430766,0.0006315246,0.003595021,0.0006329265,0.0001508869,0.0002127221,0.0004271421,0.0002952609,0.001451422],"category_scores_gemma":[0.002031202,0.0004561348,0.0004872326,0.001274629,0.0000865937,0.0001554212,0.0003187963,0.0007364504,0.0005614669],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003388376,"about_ca_system_score_gemma":0.001000888,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001872123,"about_ca_topic_score_gemma":0.001051271,"domain_scores_codex":[0.9935116,0.001109813,0.001624329,0.001186476,0.001422908,0.001144845],"domain_scores_gemma":[0.9952391,0.001899537,0.0002498885,0.001420128,0.0005481305,0.0006432129],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.961105,0.00349039,0.003959591,0.0004532211,0.001125802,0.01729492,0.008953622,0.0001946749,0.0006358138,0.00007332453,0.002367306,0.0003463714],"study_design_scores_gemma":[0.92964,0.0008358972,0.000002318709,0.0008124891,0.0004124452,0.05507036,0.006956062,0.004304945,0.0005987637,0.00008254234,0.0008285908,0.0004556123],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9749473,0.0008516727,0.0002434918,0.001266824,0.0005374823,0.01603823,0.0000469415,0.0002254113,0.005842605],"genre_scores_gemma":[0.9526615,0.000112735,0.000834894,0.00050756,0.0003571933,0.003643368,0.00008613305,0.0001532441,0.04164333],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03777544,"threshold_uncertainty_score":0.9997891,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04324566138564291,"score_gpt":0.3481351228482052,"score_spread":0.3048894614625623,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}